Streetbeat News

Products Services

AAPL

SSNLF

Steve Jobs initially envisioned the iPhone with an iPod-like flip design and clickwheel, inspired by Samsung's flip phone. This concept evolved into the iconic glass slab design with a touchscreen, revolutionizing the smartphone industry and leading Apple to become the world's biggest smartphone maker, surpassing Samsung.

Portfolio Pulse from Rounak Jain

February 26, 2024 | 4:35 pm

MSFT

Microsoft has announced its 'AI Access Principles' at the Mobile World Congress, committing to major investments, partnerships, and programs to foster innovation and competition in the AI economy. These principles guide Microsoft's operation of AI datacenter infrastructure and assets globally, aiming to empower organizations and individuals with broad technology access. The company has launched $5.6 billion in AI datacenter investments and AI skilling programs reaching over a million people, alongside public-private partnerships for responsible AI adoption and cybersecurity. Microsoft's partnership with OpenAI and the new partnership with France's Mistral AI are highlighted, emphasizing support for AI developers and ensuring choice and fairness in the AI economy. The principles also address societal responsibilities, including cybersecurity, responsible AI standards, AI skilling initiatives, and environmental sustainability of AI datacenters.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:32 pm

AZN

CTLT

IHE

LLY

NVO

PFE

Zealand Pharma's survodutide drug showed promising results in Phase 2 trials for MASH, heating up competition in the obesity and diabetes treatment market. Eli Lilly and Novo Nordisk, leaders with drugs like Mounjaro and Ozempic, reported strong Q4 results. The market is becoming crowded with around 70 weight loss drugs in development, including from AstraZeneca and Pfizer. Novo Nordisk acquired Catalent Inc to scale up production, while Eli Lilly launched LillyDirect for direct consumer sales. Shares of Novo and Eli Lilly have outperformed the broader pharmaceutical sector, as has the iShares U.S. Pharmaceuticals ETF.

Portfolio Pulse from Neil Dennis

February 26, 2024 | 4:31 pm

AKLI

Akili Inc (NASDAQ:AKLI) shares surged over 100% after announcing its partner Shionogi submitted the digital therapeutic SDT-001 for marketing approval in Japan. SDT-001, a localized version of Akili's EndeavorRx, aims to improve attention in pediatric ADHD patients. The submission follows a successful Phase 3 trial demonstrating significant improvements in ADHD symptoms with no safety concerns.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 4:29 pm

KOS

LUNR

SGRY

Surgery Partners reported weak quarterly sales, causing its shares to fall 7.8%. Other stocks like Intuitive Machines, Nyxoah, Jin Medical International, and several others also recorded losses. Notably, Intuitive Machines dropped 25.1% due to a lunar lander incident, and Kosmos Energy saw a 7% decline despite beating revenue expectations.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 4:19 pm

LOW

Home Depot (HD) reported its 11th consecutive quarterly decline with sales dropping to $34.79 billion, yet surpassing estimates. The company faces challenges from a post-pandemic slowdown, inflation, and high borrowing costs, leading to a guidance of a 1% decline in 2024 sales. Lowe's (LOW) is also expected to report a drop in Q4 revenue and a year-over-year decrease in its bottom line, affected by DIY segment softness, e-commerce challenges, lumber deflation, and competition. Both companies' outlooks may signal a weakening macroeconomic climate ahead.

Portfolio Pulse from Upwallstreet

February 26, 2024 | 4:01 pm

LRCX

The article provides an in-depth analysis of Lam Research (LRCX) and its competitors within the Semiconductors & Semiconductor Equipment industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Lam Research is highlighted for its market leadership in etch and second in deposition, significant exposure to memory chipmakers, and strong financial performance despite a revenue growth concern.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

MRK

OGN

New York Attorney General Letitia James has requested the FDA to investigate the safety of the asthma and allergy medication Singulair (montelukast), particularly its neuropsychiatric side effects in children. Despite a 'black box' warning added in 2020, there are concerns about the adequacy of current warnings, especially for pediatric patients. Merck & Co Inc (MRK), the original manufacturer, and Organon Inc (OGN), which now markets Singulair, are highlighted due to the drug's significant revenue and the lawsuits alleging they downplayed psychiatric risks.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 3:56 pm

NVS

RHHBY

Roche Holdings AG and Novartis AG announced positive results from the Phase 3 OUtMATCH study of Xolair for treating multiple food allergies, showing increased tolerance to common allergens. The FDA approved Xolair's expanded use based on this data. NVS shares slightly declined.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 3:52 pm

DELL

Dell Technologies announced the introduction of a new portfolio of commercial AI laptops and mobile workstations, leading to a rise in its shares.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 3:51 pm